Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
InChiKey: QLUWQAFDTNAYPN-LLVKDONJSA-N
Chem Senses
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary
22(6):753-768
LDN-214117 shows a high degree of selectivity for ALK2 and low cytotoxicity that could provide a template for preclinical development
SRT1720 Size:2mg solid InChiKey: QLUWQAFDTNAYPN-LLVKDONJSA-NSRT 1720, also known as CAY10559 and is a drug developed by Sirtris Pharmaceuticals intended as a small molecule activator of the sirtuin subtype SIRT1. It has similar activity in the body to the known SIRT1 activator resveratrol, but is 1000x more potent. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. A study of SRT1720